Loading
Several drugs are approved for the same cancer, but nobody tests which order works best because no company benefits from the answer. Public multi-arm trials could settle these questions efficiently.
Cooperative groups run multi-arm multi-stage (MAMS) trials comparing sequences of already-approved agents (e.g., ADC then checkpoint inhibitor versus the reverse; endocrine-CDK4/6 sequencing; TKI order in RCC), with interim futility dropping of arms and OS or TTF across the sequence as the primary endpoint. Drug supply comes from companies under a neutral-access agreement; funding from payers and public agencies who bear the cost of wrong sequences.
Shares Basket, umbrella, and platform trials, Trial design, endpoints and cost.
Shares Incentives reward me-too drugs and marginal gains, Trial design, endpoints and cost.
Shares Basket, umbrella, and platform trials, Trial design, endpoints and cost.
Shares Basket, umbrella, and platform trials, Trial design, endpoints and cost.
Shares Incentives reward me-too drugs and marginal gains, Trial design, endpoints and cost.
Shares Basket, umbrella, and platform trials, Trial design, endpoints and cost.
Shares Basket, umbrella, and platform trials, Trial design, endpoints and cost, Bladder & urothelial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/